Last reviewed · How we verify
NCT07365527: CEUSON
Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
NA trial testing Low-intensity contrast enhanced ultrasound in Liver Metastases From Colorectal Cancer in 48 participants. Currently enrolling.
15 January 2027
Quick facts
| Lead sponsor | Zealand University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 25 February 2026 |
| Primary completion | 15 January 2027 |
| Estimated completion | 15 January 2027 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
- Low-intensity contrast enhanced ultrasound
- High-intensity contrast enhanced ultrasound
Conditions studied
- Liver Metastases From Colorectal Cancer — all drugs for Liver Metastases From Colorectal Cancer →
Sponsor
Zealand University Hospital
Who can join
18 and older, any sex, with Liver Metastases From Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an investigator-initiated, randomized controlled trial enrolling patients with colorectal liver metastases. The objectives are to evaluate the safety and efficacy of contrast-enhanced ultrasound (CEUS)-mediated sonoporation as a potential therapeutic intervention and to investigate whether sonoporation can modulate the tumor microenvironment toward a more immune-active state
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07365527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Metastases From Colorectal Cancer
Currently open trials in the same condition.
- NCT07177742 — Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis · recruiting
Other Zealand University Hospital trials
Trials by the same sponsor.
- NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
- NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
- NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07304375 — Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07365527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07365527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing